Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.

CONCLUSIONS: The cost comparison between mepolizumab and  omalizumab in immunoglobulin E mediated eosinophilic asthma patients  suggests a use of the lower cost drug, promoting price competition.  Additionally, prioritizing its use among non immunoglobulin E-mediated  severe refractory eosinophilic asthma patients and ≥ 500 eosinophils/μL  plasma level patients, would improve its efficiency as well as  reducing its budgetary impact.
PMID: 31705642 [PubMed - in process]

Source: Farmacia Hospitalaria - October 31, 2019 Category: Drugs & Pharmacology Authors: García-Mochón L, Gil-Sierra MD, Alegre-Del Rey EJ, Alarcón de la Lastra-Romero C, Sánchez-Hidalgo M Tags: Farm Hosp Source Type: research